Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
141 participants
OBSERVATIONAL
2017-05-01
2023-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevention of Contrast-induced Nephropathy in Patients With Acute Myocardial Infarction
NCT01160627
Continuous Regional Arterial Infusion of Low Molecular Weight Heparin in Patients With Severe Acute Pancreatitis
NCT01626911
Activation of Polyamine Catabolism in Patients With Acute Pancreatitis
NCT00484042
Pharmacokinetics of Apixaban in Nephrotic Syndrome
NCT02599532
Dexmedetomidine Hydrochloride in the Prevention of Organ Failure Following Severe Acute Pancreatitis
NCT02691598
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients with acute pancreatitis admitted to Skåne University Hospital in Malmö
Acute pancreatitis is defined as minimum 2 out of following: amylase levels \>3 times upper reference limit, clinical signs of acute pancreatitis, imaging findings of acute pancreatitis)
Exclusion criteria:
\<18 years of age
\>72 hours from onset of symptom until first sampling
Patients with immunosuppression or autoimmune diseases are excluded from som parts of the study.
Methods: Serum and plasma is sampled repeatedly during the hospital admission. Pre defined protocols are used for data collections of relevant clinical information.
Specific aspects of inflammation, thrombin generation, platelet function and Microparticles will be analysed in serum or plasma during the first consecutive days of acute pancreatitis.
Biomarkers for severe disease as well as correlation between inflammation and coagulopathy will be investigated.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mild acute pancreatitis
Groups are defined by the Revised Atlanta classification. Anticipated 60% mild, 30% moderate and 10% severe patients
Exploratory for different markers
Test biomarkers for development of mild, moderate or severe disease
moderately severe acute pancreatitis
Groups are defined by the Revised Atlanta classification. Anticipated 60% mild, 30% moderate and 10% severe patients
Exploratory for different markers
Test biomarkers for development of mild, moderate or severe disease
severe acute pancreatitis
Groups are defined by the Revised Atlanta classification. Anticipated 60% mild, 30% moderate and 10% severe patients
Exploratory for different markers
Test biomarkers for development of mild, moderate or severe disease
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exploratory for different markers
Test biomarkers for development of mild, moderate or severe disease
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lund University
OTHER
Region Skane
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sara Regnér, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Region Skåne and Lund University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Skåne University Hospital
Malmo, Skåne County, Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016/490
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.